Hutchison MediPharma's VEGFR Inhibitor Fruquintinib Accepted By SFDA
This article was originally published in PharmAsia News
Executive Summary
A few months after its first independently developed anti-cancer drug, Sulfatinib, was officially accepted for fast-track approval by China's State FDA, Shanghai-based Hutchison MediPharma submitted its application for registration of its self-developed VEGFR inhibitor Fruquintinib